Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Black Diamond Therapeutics, BDTX-1535 and NSCLC
Black Diamond reports encouraging Phase 2 data for BDTX-1535
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment of patients with recurrent EGFR-mutant non-small cell lung cancer, or NSCLC.
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Black Diamond Therapeutics Inc (BDTX) Stock’s 0.98% Increase This Year: What’s the Story?
Raymond James has recently initiated Black Diamond Therapeutics Inc (BDTX) stock to Outperform rating, as announced on July 31, 2024, according to Finviz. Earlier, on July 14, 2023, Piper Sandler had initiated the stock to Overweight.
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday,
FierceBiotech
1d
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
ENDPOINTS NEWS
1d
Black Diamond treads water on small snapshot of Phase 2 lung cancer data
Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...
Voiceofmotown on MSN
21h
WVU Projected to Go Bowling for the Black Diamond Trophy
Neal Brown, who is coming off of a 9-win campaign in 2023, will have to find four more wins if he hopes for his team to ...
Enumclaw Courier-Herald on MSN
7d
Oakpointe’s developments are 20% completed. What’s next? Recreation
Ten Trails and Lawson Hills neighborhoods developer Oakpointe is asking the Black Diamond City Council to consider recreation ...
Mexico News Daily
3d
Emma Coronel, wife of ‘El Chapo’ Guzmán, to model at Milan Fashion Week
Emma Coronel, a former beauty queen, was released from prison a year ago, and will now be a runway model at Milan Fashion ...
Latin Times on MSN
5d
El Chapo's wife Emma Coronel to Debut as an International Model at Milan Fashion Week
After two and a half years in prison, El Chapo Guzmán's wife Emma Coronel debuts as a model in prestigious Milan Fashion Week ...
7d
‘The Poky Dot’ building put up for sale
According to a listing from real estate group Black Diamond Realty, “The Poky Dot” building located at 1111 Fairmont Avenue ...
1d
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
BDTX-1535
Phases of clinical research
Feedback